Remove Biosimilars Remove Hospitals Remove Medication Therapy Management (MTM)
article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

Timely implementation is particularly critical for beneficiaries requiring immediate mental health or substance use treatment, where delays can lead to worsening health outcomes, increased hospitalization rates, and preventable mortality. 38 Furthermore, CMS should include manufacturer rebates in the definition of “negotiated price.”